Skip to content

Study on the correlation between PMOP and ERa-AMPK signaling pathway and Chinese medicine intervention

Study on the correlation between PMOP and ERa-AMPK signaling pathway and Chinese medicine intervention

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300068176
Enrollment
Unknown
Registered
2023-02-09
Start date
2022-05-31
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoporosis

Interventions

Patients with postmenopausal osteoporosis:No
Non-osteoporosis female patients:No

Sponsors

The Third Affiliated Hospital of Guangzhou University of TCM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
23 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Inclusion criteria of observation group: (1) Osteoporosis diagnosis criteria were met, and TCM syndrome differentiation was all kidney Yang deficiency syndrome;(2) women who have had normal menopause for more than 1 year and are older than 45 years;(3) Obtain the right to know and voluntarily cooperate with the observer. 2. Control group included criteria (1) bone mineral density measurement T value > -2.5SD;(2) women between 45 and 70 years old;(3) Obtain the right to know and voluntarily cooperate with the observer.

Exclusion criteria

Exclusion criteria: 1. Exclusion criteria (1) Those who do not meet the above diagnostic criteria of Chinese and Western medicine;(2) Menopause less than 1 year, age over 70 years old;(3) Women undergoing unnatural menopause such as ovarian resection or those younger than 45 years old;(4) patients with severe primary diseases such as liver and kidney system, endocrine system and cerebrovascular system, mental disorders and senile dementia;(5) Rheumatoid arthritis, hyperparathyropathy, osteomalacia, multiple myeloma and other secondary osteoporosis and other comorbidities;(6) advanced disease, obvious deformity resulting in disability and loss of labor force;(7) Patients who had used anti-osteoporosis drugs within six months prior to the start of treatment;(8) Clinical treatment is not guaranteed. 2. Exclusion criteria (1) Drugs that affect bone metabolism, such as estrogen and diclinate, have been taken in the last three months;(2) One of the following conditions: malignant tumor, limb trauma fracture, burn, dementia, cerebrovascular accident, severe infection, etc.;(3) those with congenital diseases, such as sclerosing bone disease;(4) Patients with mental illness and those who could not cooperate with the study.

Design outcomes

Primary

MeasureTime frame
ERa mRNA;LKB1 mRNA;CaMKKß mRNA;AMPKa1 mRNA;ACC mRNA;ERa protein;LKB1 protein;p-LKB1 protein;CaMKKß protein;AMPKa1 protein;p-AMPKa1 protein;ACC protein;p-ACC protein;Bone mineral density;

Secondary

MeasureTime frame
Age;Height;weight;Body mass index;

Countries

China

Contacts

Public ContactSHAO MIN,YANG FENG

The Third Affiliated Hospital of Guangzhou University of TCM

shaomin98@aliyun.com13288809366,18827022347

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026